Pfizer Targets Wockhardt In Generic Toviaz Suit

Law360, New York (August 05, 2013, 2:52 PM ET) -- Pfizer Inc. sued two units of rival Wockhardt Ltd. in Delaware federal court Friday, alleging its planned generic version of overactive-bladder medication Toviaz infringes a handful of patents covering the drug.

According to Pfizer, Wockhardt USA LLC's plans to make fesoterodine fumarate extended-release tablets infringes five patents covering Topiaz's active ingredient — U.S. Patent Numbers 6,858,650; 7,384,980; 7,855,230; 7,985,772; and 8,338,478 — which are exclusively licensed to Pfizer by UCB Pharma GmbH.

“Plaintiffs will be harmed substantially and irreparably if Wockhardt is not enjoined from infringing...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required